FDA Grants Accelerated Approval to Inovio's DNA Immunotherapy Voceryq; Precigen Shares Plunge 27% After Hours
FDA granted accelerated approval to Inovio's (INO) DNA immunotherapy Voceryq for recurrent respiratory papillomatosis. Inovio shares surged 300% after hours, while Precigen's (PGEN) shares dropped 27% on market competition concerns. Voceryq is the first plasmid DNA-based immunotherapy approved in the U.S. and the second treatment for the disease.
How this was made
The 30-second read
Why it matters
Regulatory approval creates a new revenue stream for Inovio while disrupting Precigen's monopoly, likely reshaping the rare‑disease biotech landscape.
Market read
The approval is a primary catalyst for both stocks, driving a sharp rally in INO and a sell‑off in PGEN, with broader implications for DNA‑based therapies.
What to watch
Potential reimbursement hurdles and the need for additional efficacy data could temper market enthusiasm.
Background
Inovio's Voceryq is the first plasmid DNA immunotherapy approved in the U.S., targeting recurrent respiratory papillomatosis, a rare HPV‑driven disease.
Ticker impact
FDA granted accelerated approval to Inovio's Voceryq, driving shares up >300% in after‑hours trading.
likely upward pressure as investors price in first commercial product and potential revenue.
Regulatory approval is a material catalyst; the market reacted strongly and the product addresses an unmet need.
Precigen's shares fell 27% after hours as Inovio's approval threatens its monopoly on RRP therapy.
likely downward pressure as market reassesses future revenue from Papzimeos.
The approval introduces a direct competitor to Precigen's sole product, eroding its market share.
Market effects
May spur interest in DNA‑based immunotherapies and affect other rare‑disease biotech stocks.
U.S. biotech sector sees heightened volatility as regulatory approvals gain focus.
Highlights FDA's willingness to approve novel gene‑therapy platforms, influencing global biotech pipelines.
Counterpoint
Inovio may face commercialization challenges and post‑approval trial requirements, limiting upside.
Key entities
- CompanyInovio Pharmaceuticals
US biotech receiving FDA accelerated approval for Voceryq.
- CompanyPrecigen
Current market leader with Papzimeos, facing competitive pressure.
- RegulatorFDA
U.S. agency granting accelerated approval.
